Open AccessSerum cyfra21-1 as a biomarker in patients with nonsmall cell lung cancer
Author(s) -
Guangshun Wang,
Hongjie Zhao,
Xuejun Shi,
Jinbo Liu,
Zhengang Chen
Publication year - 2014
Publication title -
journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/0973-1482.145878
Subject(s) - medicine , biomarker , lung cancer , confidence interval , cytokeratin , oncology , serology , receiver operating characteristic , retrospective cohort study , gastroenterology , immunology , immunohistochemistry , antibody , biochemistry , chemistry
The purpose of this retrospective study was to evaluate the clinical value of serum cytokeratin-19-fragment (cyfra21-1) as a biomarker in nonsmall cell lung cancer (NSCLC).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom